{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T10:10:32Z","timestamp":1708769432107},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,3,31]],"date-time":"2008-03-31T00:00:00Z","timestamp":1206921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Medical Primatology"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Enrofloxacin is used for treating Shigellosis in non\u2010human primates; however, there are no reports describing its pharmacokinetics in rhesus monkeys. Pharmacokinetic data in intended target species (rhesus) help to determine the proper dose regimen. Blood levels of enrofloxacin and ciprofloxacin (enrofloxacin\u2019s active metabolite), were determined after either intramuscular or oral dosing of enrofloxacin for 7\u2003days in a cross\u2010over study. Levels of both antibiotics were determined by solid phase extraction followed by reversed\u2010phase chromatography with tandem mass spectrometry. Results indicate enrofloxacin half\u2010life after intramuscular dosing is estimated to be 2.4\u2003hours. Enrofloxacin given either intramuscular or p.o. rapidly achieves satisfactory therapeutic blood levels of enrofloxacin or ciprofloxacin in rhesus monkeys. Results from these pharmacokinetic study parallel values published for other animal species. Our results show use of enrofloxacin is effective in managing<jats:italic>Shigella<\/jats:italic>infections in rhesus monkeys based upon achieving these blood drug levels.<\/jats:p>","DOI":"10.1111\/j.1600-0684.2008.00280.x","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T06:20:30Z","timestamp":1207030830000},"page":"177-183","source":"Crossref","is-referenced-by-count":6,"title":["A pharmacokinetic study of enrofloxacin and its active metabolite ciprofloxacin after oral and intramuscular dosing of enrofloxacin in rhesus monkeys (<i>Macaca mulatta<\/i>)"],"prefix":"10.1111","volume":"37","author":[{"given":"Hilton","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Hasselschwert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Handt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kastello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2460\/ajvr.1996.57.04.547","article-title":"Penetration of enrofloxacin and ciprofloxacin into breast milk and pharmacokinetics of drugs in lactating rabbits and neonatal offspring","volume":"57","author":"Aramayona J","year":"1996","journal-title":"Am J Vet Res"},{"key":"e_1_2_6_3_2","first-page":"602","article-title":"Lack of reactivation of shigellosis in naturally infected enrofloxacin\u2010treated cyomologus monkeys after exogenous immunosuppression","volume":"47","author":"Black\u2010Schultz L","year":"1997","journal-title":"Lab Anim Sci"},{"key":"e_1_2_6_4_2","first-page":"1159","volume-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"Chambers HenryF","year":"2001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.3.353"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1995.tb00604.x"},{"key":"e_1_2_6_7_2","first-page":"240","article-title":"Enrofloxacin treatment of long\u2010tailed macaques with acute bacillary dysentery due to multi\u2010resistant Shigella flexneri IV","volume":"42","author":"Line AS","year":"1992","journal-title":"Lab Anim Sci"},{"key":"e_1_2_6_8_2","first-page":"1159","volume-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"Petri WilliamA","year":"2001"},{"key":"e_1_2_6_9_2","volume-title":"The Principles of Humane Experimental Techniques","author":"Russell WMS","year":"1959"},{"key":"e_1_2_6_10_2","unstructured":"ScheerM:Concentration of active ingredient in the serum and in tissues after oral and parenteral administration of Baytril\u00aeBayer Technical Info.Bayer HealthCare LLC Shawnee Mission Kansas USA1997;104\u201318."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/02652039209374080"}],"container-title":["Journal of Medical Primatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0684.2008.00280.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0684.2008.00280.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T09:09:09Z","timestamp":1708765749000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0684.2008.00280.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,28]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1111\/j.1600-0684.2008.00280.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0684.2008.00280.x","archive":["Portico"],"relation":{},"ISSN":["0047-2565","1600-0684"],"issn-type":[{"value":"0047-2565","type":"print"},{"value":"1600-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,28]]}}}